Trademarkia Logo

Canada

C$
Trademark Search in Canada
CHINESE CHARACTERS KE LUO XIN
CHINESE CHARACTERS KE LUO XIN
REGISTERED

on 28 Sept 2021

Last Applicant/ Owned by

CHENGDU KANGHONG PHARMACEUTICALS GROUP CO. LTD.

No. 36, Shuxi Rd. Jinniu DistrictChengdu, 610000, Sichuan

CN

Serial Number

1910356 filed on 19th Jul 2018

Registration Number

TMA1110375 registered on 28th Sept 2021

Registration expiry Date

28th Sept 2031

Correspondent Address

NEOMARK LTD.

7450 rue Saint-HubertMontréal

QUEBEC

CA

H2R2N3

CHINESE CHARACTERS KE LUO XIN

Trademark usage description

medicines for humans for pharmaceutical preparations for the treatment and prevention of cardiovascular, hematological, bone, respiratory, gastroenter Read More

Vienna Information


28 . 3 . 0

Inscriptions in Chinese, Japanese or Korean charactersInscriptions en caractères chinois, japonais ou coréens

Classification Information


Class [005]
Medicines for humans for pharmaceutical preparations for the treatment and prevention of cardiovascular, hematological, bone, respiratory, gastroenterological, diabetic and ocular diseases and disorders; Medicines for humans for pharmaceutical preparations for the treatment and prevention of dermatological diseases and disorders, namely, dermatitis, skin pigmentation diseases, sexually transmitted diseases, eczema, psoriasis; Medicines for humans for pharmaceutical preparations for the treatment and prevention of central nervous system diseases and disorders, namely, central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases, encephalitis, epilepsy, Alzheimer's, cerebral palsy, Parkinson's disease; Medicines for humans for pharmaceutical preparations for the treatment and prevention of endocrinological diseases and disorders, namely growth and thyroid disorders; Medicines for humans for pharmaceutical preparations for the treatment and prevention of circulatory diseases and disorders, namely anemia and aplastic anemia diseases; Medicines for humans for pharmaceutical preparations for the treatment and prevention of stomach ulcers; Medicines for humans for pharmaceutical preparations for the treatment and prevention of digestive diseases and disorders, namely indigestion, chronic gastritis accompanied by heartburn, belching, nausea, vomiting, early satiety, epigastralgia and other gastrointestinal symptoms and chronic lithogenous cholecystitis disease; Medicines for humans for pharmaceutical preparations for the treatment and prevention of hormonal diseases and disorders, namely thyroid diseases and disorders, diabetes, hypertension, hyperlipidemia and metabolic arthritis diseases; Medicines for humans for pharmaceutical preparations for the treatment and prevention of muscular dystrophy; Medicines for humans for pharmaceutical preparations for the treatment and prevention of rheumatic diseases and disorders, namely rheumatic arthritis, arthralgia, Primary lower back pain diseases; Medicines for humans for pharmaceutical preparations for the treatment and prevention of immune system diseases and disorders, namely, autoimmune diseases, immunologic deficiency syndromes; Medicines for humans for pharmaceutical preparations for the treatment and prevention of metabolic diseases and disorders, namely diabetes, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia, bulimia nervosa, anorexia, obesity and hypothyroidism; Pharmaceuticals to treat and prevent diabetes, coughs, colds, influenza virus, headaches and allergic reactions; Anti-infectives; Anti-inflammatories; Human vaccines; Antidiabetic pharmaceutical preparations; Pharmaceutical preparations for the treatment of diabetes; Anti-diabetic pharmaceuticals; Pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely diabetes, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia, bulimia nervosa, anorexia, obesity and hypothyroidism; Pharmaceutical preparations, namely, ophthalmics; Pharmaceutical preparations for the treatment of ophthalmic diseases and conditions; Asthmatic tea; Slimming tea for medical purposes; Crude drugs for the treatment of central nervous system diseases, namely hypertension, hyperlipidemia, schizophrenia and melancholia, digestive system diseases, namely dyspepsia, chronic gastritis, chronic lithogenous cholecystitis, chronic cholecystitis and gall-stone, ophthalmology system diseases, namely wet Age-related Macular Degeneration (AMD), and other diseases, namely fever, eye infections, mouth sores, sore throat, swollen gums, constipation, pharyngitis, tonsillitis, gingivitis, upper respiratory infection (URI), acute bronchitis, diabetes and nephropathy; Empty capsules for pharmaceuticals; Medicines for humans used for the treatment of choroidal neovascularization induced by high myopia, macular edema induced by retinal vein occlusion, diabetic macular edema, wet age-related macular degeneration accompanied by very low vision acuity, the inhibition of neovascularization, back-of-the-eye neovascularization, aged-related macular degeneration, retinal vein occlusion, neoplastic disease and cancer, angiogenesis disease; Pharmaceutical preparations for the treatment of diabetes, cardiovascular disease and disorder, neoplastic disease and disorder, cancer, angiogenesis disease and disorder, ophthalmic diseases and disorder, aged-related macular degeneration; Pharmaceutical preparations for the treatment of immune system diseases and disorders, namely, autoimmune diseases, immunologic deficiency syndromes; Pharmaceutical preparations for the treatment of mental diseases and disorder, namely schizophrenia, Major Depressive Disorder and anxiety; Injectable preparations for medical use, namely, for the treatment of oculopathy, choroidal neovascularization induced by high myopia, macular edema induced by retinal vein occlusion, diabetic macular edema, wet age-related macular degeneration accompanied by very low vision acuity, the inhibition of neovascularization, back-of-the-eye neovascularization, aged-related macular degeneration, retinal vein occlusion, neoplastic disease, angiogenesis disease and cancer; Aqueous formula, namely, water-based pharmaceutical preparations for the treatment of cardiovascular disease and disorder, neoplastic disease and disorder, ophthalmic diseases and disorder, inflammation; Aqueous formula, namely, water-based pharmaceutical preparations for the treatment of immune system diseases and disorders, namely, autoimmune diseases, immunologic deficiency syndromes; Biochemical drugs and preparations for medical use, namely, for the prevention, treatment and alleviation of angiogenesis disease, oculopathy, neoplastic disease, cancer; Medicines and pharmaceutical preparations, namely, anti-anginal drugs, anti-parkinson drugs, anti-bacterials, anti-cholinergics, anti-convulsants, anti-emetics, anti-fungals, anti-hypertensives, antineoplastics, anti-malarials, hemostatics, antihistamines, hormones, sedatives/hypnotics, narcotic analgesics, narcotic antagonists, peripheral vasodilators, psychotropic drugs, diuretics, vitamin; Medicines and pharmaceutical preparations for use in dermatology, namely, dermatitis, skin pigmentation diseases, sexually transmitted diseases, eczema, psoriasis; Alcohol for topical use; Isopropyl alcohol for medical purposes; Rubbing alcohol; Gases and gas mixtures for use in medical imaging; Gases for dental purposes; Gases for medical use; All purpose disinfectants; Nutritive substances for microorganisms, namely nutrient substrate prepared by the combination of different nutrients for the growth and reproduction of microorganisms; Acai powder dietary supplements; Albumin dietary supplements; Alginate dietary supplements; Bee pollen used as a dietary supplement; Casein dietary supplements; Colostrum dietary supplements; Diet capsules; Diet pills; Dietary fiber to aid digestion; Dietary fibre as a food additive; Dietary fibre for treating constipation; Dietary fibre for use as an ingredient in the manufacture of dietary supplements; Dietary supplements consisting of amino acids; Dietary supplements consisting of trace elements; Dietary supplements for controlling cholesterol; Dietary supplements for general health and wellbeing; Dietetic sugar substitutes adapted for medical purposes; Flaxseed dietary supplements; Flaxseed oil dietary supplements; Glucose dietary supplements for animals; Lecithin dietary supplements; Linseed dietary supplements; Linseed oil dietary supplements; Mugwort dietary supplements; Natural dietary supplements for treating claustrophobia; Pollen dietary supplements; Propolis dietary supplements; Soy protein dietary supplements; Vitamin and mineral dietary supplements; Wheat dietary supplements; Wheatgrass dietary supplements; Yeast dietary supplements; Zinc dietary supplements; Depuratives for the body; Anti-infective preparations for veterinary purposes; Antibiotics for veterinary purposes; Hormones for veterinary purposes; Insecticidal veterinary washes; Laxatives for veterinary purposes; Pain relief medication for veterinary purposes; Veterinary pharmaceutical preparations for animals and poultry to give newborn animals and birds a healthy start; Veterinary pharmaceutical preparations for periodontal diseases; Veterinary pharmaceutical preparations for respiratory and reproductive diseases in cattle; Veterinary pharmaceutical preparations for the treatment of arthritis, muscle soreness and sprains; Veterinary pharmaceutical preparations for the treatment of bacterial infections in dogs; Veterinary pharmaceutical preparations for the treatment of parasites; Veterinary pharmaceutical preparations for the treatment of vitamin deficiencies; Veterinary vaccines; Pesticides; Dental lacquer; Electrolyte drinks for medical purposes; Vitamin preparations in the form of meal replacement drinks and powders.


Classification kind code

11

Mark Details


Serial Number

1910356

Mark Type

Trademark

Legal History


Show more

Action TakenStatus
Submitted for opposition 191
on 4th Aug 2021
Registration Fee Notice Sent
Submitted for opposition 190
on 4th Aug 2021
Registration Pending
Submitted for opposition 42
on 12th May 2021
Advertised
Submitted for opposition 26
on 15th Apr 2021
Approved
Submitted for opposition 27
on 15th Apr 2021
Approval Notice Sent
Submitted for opposition 22
on 3rd Sept 2020
Search Recorded
Submitted for opposition 20
on 3rd Sept 2020
Examiner's First Report
Submitted for opposition 31
on 25th Jul 2018
Formalized
Submitted for opposition 30
on 19th Jul 2018
Filed
Submitted for opposition 1
on 19th Jul 2018
Created